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Aspartame (a-Laspartyl-L-phenylalanine 1-methylester) is a dipeptide low-calorie artiﬁcial sweetener that is widely used as a
nonnutritive sweetener in foods and drinks. The safety of aspartame and its metabolic breakdown products (phenylalanine,
aspartic acid and methanol) was investigated in vivo using chromosomal aberration (CA) test and sister chromatid exchange
(SCE) test in the bone marrow cells of mice. Swiss Albino male mice were exposed to aspartame (3.5, 35, 350mg/kg body weight).
Bone marrow cells isolated from femora were analyzed for chromosome aberrations and sister chromatid exchanges. Treatment
with aspartame induced dose dependently chromosome aberrations at all concentrations while it did not induce sister chromatid
exchanges. On the other hand, aspartame did not decrease the mitotic index (MI). However, statistical analysis of the results show
that aspartame is not signiﬁcantly genotoxic at low concentration.
1.Introduction
Aspartame (a-Laspartyl-L-phenylalanine 1-methylester) is
a dipeptide artiﬁcial sweetener, that is, widely used as a
nonnutritive sweetener in food and drinks. Aspartame was
discovered in 1965. In 1981, it became the ﬁrst low-calorie
sweetener approved by the Food and Drug Administration.
The chemical structure and formula of aspartame is shown
in Figure 1.
Toxicological studiescarriedoutwithaspartamerevealed
that doses of aspartame required for harmful action would
be very high and unrealistic [1]. Molinary [2] reported that
aspartame was not mutagenic in Ames test. Also, aspartame
was found not mutagenic in TA 100 and TA 98 Salmonella
tester strains after nitrosation [3]. Moreover, It was not
clastogenic in vivo,i nm i c e[ 4]. And it was reported that
aspartame did not induce DNA damage in rat hepatocytes
[5]. Mukhopadhyay et al. [6]r e p o r t e din vivo coexposure
of aspartame and acesulfame potassium was negative for
the induction of chromosome aberrations in male Swiss
mice bone marrow cells. Although, Ishii [7] reported that
aspartame does not cause brain cancer in rats. But Olney
et al. [8], founded that aspartame might be associated with
increased incidence of brain tumors. In addition, Gurney et
al. [9], reported aspartame consumption in relation to brain
tumor risk in children. Hence Butchko et al. [10]r e v i e w e d
a study on safety of Aspartame and reported that it is safe.
Whereas, Renc¨ uzo˘ gullar et al. [11], found that Aspartame
induced chromosomal aberration at all concentrations (500,
1000 and 2000µg/mL) and treatment periods (24 and 48h)
in human lymphocytes dose dependently while it did not
cause sister chromatide exchanges. In addition, Aspartame
induced micronuclei at the highest concentrations only.
The mitotic index was depressed in all used Aspartame
concentrations. Whereas the replication index was decreased
in the highest dose in the 48h treatment. However Soﬀritti et
al. [12, 13], reported evidence of Aspartame carcinogenicity
(combined leukemia/lymphoma).
Bandyopadhyay et al., evaluated the genotoxic potential
of of the low-dose range (7–37mg/bwkg) of Aspartame by
comet assay in the bone marrow cells of Swiss Albino mice.
The comet parameters of DNA were increased in the bone
marrow cells due to the sweetener-induced DNA strand
breaks,asrevealedbyincreasedcomet-tailextentandpercent
DNA in the tail [14].
The “acceptable daily intake” of aspartame, established
by FDA, is 50mg/kg; a food intake survey conducted by U.S.2 Comparative and Functional Genomics
Table 1: Total chromosomal aberration in mouse bone marrow following exposure of aspartame.
Treatment Chromosomal aberrations/250 cells
(mg/kg body weight) G
  GB
  BD C ±SD CA/Cell±SD
Control 5 0 5 0 0.02±0.00 0.02±0.00
3.5 3 0 5 0 0.02±0.01ns 0.02±0.00ns
35 7 1 8 1 0.04±0.01∗∗ 0.04±0.01∗∗
350 80 1 10 0 . 0 5 ±0.01∗∗ 0.05±0.01∗∗
G ,G= chromatid and chromosome gaps; B ,B= chromatid and chromosome breaks; DC = damaged cells with at least one CA (excluding gaps); CA =
chromosomal aberrations; SD = standard deviation of the mean; ∗ signiﬁcant with both control and 3.5mg/kg body weight at level 0.01; ns not signiﬁcant
with vehicle control.
Table 2: One-way ANOVA analysis of damaged cells showing diﬀerences among treatment groups.
Sources of variation Degrees of freedom Sum of squares Mean sum of squares F ratio
Among groups 3 203.350 67.783 21.866∗∗
Within groups (errors, replicates) 16 49.600 3.100
∗Signiﬁcant at level 0.01.
Table 3: Frequency of SCE and MI in mouse bone marrow following exposure of aspartame.
Treatment (mg/kg body weight) Min-Max SCE SCE/cell±SE MI±SE
Control 0–17 3.20±0.73 2.80±0.37
3.5 3–10 4.60±0.40 2.20±0.37
35 3–15 4.40±0.81 2.00±.0.55
350 3–20 5.40±0.93 2.00±0.32
A total 150 cells were scored for the SCE assay; 1000 cells from each animal were scored for MI.
Department of Agriculture found some people in the U.S.
consumed more than 16mg/kg/day [15].
There have been multiple genotoxicity studies of aspar-
tame each of which is inadequate for judging on its eﬀect.
The purpose of the present study was to determine whether
and to what extent aspartame would induce chromosomal
aberrations and sister chromatid exchanges. Bone marrow
cells were chosen as indicator cells for their high sensitivity
to clastogens [16].
2.MaterialsandMethods
The studies were conducted with male Swiss Albino mice
aged 8–10wk, weighing 20–25g. Each experimental group
consisted of ﬁve animals for each treatment and a control.
They were maintained under conditions of ambient room
temperature and relative humidity. The test substance aspar-
tame was obtained from Sigma (Cat. no: A5139). Aspartame
was dissolved in distilled water. Three concentrations: (i)
3.5mg/kg body weight, (ii) 35mg/kg body weight, and
(iii) 350mg/kg body weight were administered orally. These
concentrations were selected according to cytotoxicity of
aspartame. Control animals were treated with the solvent
only. The animals were killed 24hr later. Femoral bone
marrow cells were analyzed for Chromosomal Aberration
Assay (CA Assay), Sister Chromatid Exchange Assay (SCE
Assay) and Mitotic Indices (MI).
Animals were intraperitoneally injected with BrdU
1.5mg/g of body weight. 22 hours after BrdU injection ani-
mals were injected subcutaneously with 0.1mL Colchicine
solution (4mg/10mL distilled water)/10g body weight. Two
hours later, animals were sacriﬁced by cervical dislocation
andbothfemursweredissectedtoobtainbonemarrow;bone
marrow was obtained by injecting a phosphate-buﬀered
saline solution into one end of the femur. Bone marrow
cells were routinely processed by the standard procedure
and slides were coded and stained in diluted Giemsa [17].
50 metaphase cells were scored per animal. Chromatid
and chromosome gaps, breaks, and rearrangements were
evaluated in accordance with the method of Tice et al. [18].
The percentage of damaged cells (% DC) and chromosomal
aberrations per cell (CA/cell) were calculated for each
animal. Gaps were excluded from the analysis.
For the SCEs, slides were dried for at least 24 hours and
stained using the ﬂuorescence plus Giemsa method [19, 20].
SCE frequency was scored in 30 metaphases per mouse
under secondmetaphases. The metaphaseswereexamined at
1000× magniﬁcation. The results were used to determine the
mean number of SCE (SCE/cell). In addition, The Mitotic
Index(MI)wasdeterminedasthenumberofmetaphasesperComparative and Functional Genomics 3
Table 4: One-way ANOVA analysis of SCE and MI showing diﬀerences (if any) among treatment groups.
Sources of
variation Sum of squares DF Mean square F Sig.
Between groups 12.400 3 4.133
SCE/cell Within groups 44.400 16 2.775 1.489 0.255(ns)
Total 56.800 19
Between groups 2.150 3 0.717
MI Within groups 13.600 16 0.850 .843 0.490(ns)
Total 15.750 19
P> .05.
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Figure 1: Structure of aspartame (N-l-alpha-aspartyl-l-phenylala-
nine 1-methylester).
1000 cells from each animal. The MI explained the eﬀects of
aspartame on G2 stage of cell cycle.
Analysis of variance (ANOVA) was done to observe
signiﬁcant diﬀerences between the individual groups and
Student’s t-test was carried to compare the data of individual
dose with that of the control. The level of signiﬁcance was
established at P=.01.
3. Result andDiscussion
Table 1 presents data on the observation of chromosomal
aberrations in the bone marrow cells of mice following expo-
sure to aspartame. Aspartame induced a signiﬁcant increase
of chromosome aberration frequencies at concentrations
35mg/kg body weight and 350mg/kg body weight com-
pared to concentrations 3.5mg/kg body weight and control
(Table 2). The aberrations were mainly chromatid in type.
However aspartame did not induce a signiﬁcant increase
of SCEs at any concentrations and treatment compared to
control. Also, aspartame did not decrease the MI at any
investigated concentrations for 24 hours treatment periods
when compared with control (Tables 3 and 4).
In this study, Aspartame signiﬁcantly induced CA at
concentrations 35mg/kg body weight and 350mg/kg body
weight. Nevertheless, aspartame did not induce the SCE or
decreased the MI. While Renc¨ uzo˘ gullar et al., reported that
Aspartame induced CAs at all concentrations (500, 1000
and 2000mg/mL) and treatment periods (24 and 48h) dose
dependently, although it did not induce SCEs. However,
Aspartame showed a cytotoxic eﬀect by decreasing the MI
at all concentrations and treatment periods dose-dependentl
in human lyphocytes [11]. Furthermore Mukhopadhyay et
al., found that treatment with diﬀerent doses of Aspartame
in combination with acesulfame-K induced weak clastogenic
eﬀects in the bone marrow cells of mice [6].
Aspartame is hydrolysed in the gut to yield aspartic acid,
phenylalanine, methanol, and cyclised diketopiperazine [21,
22].Shephardetal.[23],reportedthatAspartamehasaweak
mutagenic eﬀect after nitrosation. However, Butchko et al.
[10], reported that Aspartame is safe and it was also reported
that ASP was not mutagenic and clastogenic in animals [4,
5]. However, it must be taken into account that to determine
the degree of disassociation of Aspartame as well as studying
long-term accumulations in animals and humans.
According to these results, we can conclude that aspar-
tame have a genotoxic risk. Therefore, it is necessary to be
careful when using it in food and beverages as a sweetener
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